In this session from the WFH 2020 Virtual Summit, Steve Kitchen, Emmanuel Favaloro, Robert Gosselin and Geoffrey Kershaw discuss:

• How the emergence of chromogenic factor VIII testing has illuminated both discrepancies between testing methods and potential issues associated with product potency assessment
• How the creation of B-domain deleted recombinant factor VIII replacement product has initiated the first real challenge for clinical laboratories to accurately monitor the advances in hemophilia replacement therapy
• How the clinical laboratory may not possess the ideal laboratory test(s) for monitoring these new-age therapies, and it may be that a single F8 testing platform may not be adequate
• A description of the EHL products and the optimal or acceptable laboratory F8 testing platforms